

Reference number(s)
3444-H

SPECIALTY QUANTITY LIMIT PROGRAM

OXBRYTA (voxelotor)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Oxbryta 500 mg tablet	90 per 30 days	150 per 30 days	Sickle cell disease: 1,500 mg orally once daily Dose modifications: <ul style="list-style-type: none"> • Severe hepatic impairment: 1,000 mg orally once daily • Strong CYP3A4 inhibitors or fluconazole: 1,000 mg orally once daily • Strong or moderate CYP3A4 inducers: 2,500 mg orally once daily

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

- Oxbryta [package insert]. South San Francisco, CA: Global Blood Therapeutics, Inc.; December 2019.